{"id":28018,"date":"2026-11-06T17:11:38","date_gmt":"2026-11-06T16:11:38","guid":{"rendered":"https:\/\/lluita.org\/les-terapies-car-t-obren-una-nova-via-per-combatre-infeccions-greus-en-pacients-immunocompromesos\/"},"modified":"2026-11-10T17:50:10","modified_gmt":"2026-11-10T16:50:10","slug":"les-terapies-car-t-obren-una-nova-via-per-combatre-infeccions-greus-en-pacients-immunocompromesos","status":"publish","type":"post","link":"https:\/\/lluita.org\/en\/les-terapies-car-t-obren-una-nova-via-per-combatre-infeccions-greus-en-pacients-immunocompromesos\/","title":{"rendered":"CAR-T therapies open up a new avenue for tackling severe infections in immunocompromised patients"},"content":{"rendered":"<p><span data-contrast=\"auto\">CAR-T therapies, best known for their use in certain blood cancers, could have a <\/span><b><span data-contrast=\"auto\">new application in the field of infectious diseases.<\/span><\/b><span data-contrast=\"auto\"> A scientific review involving researchers from the <\/span><a href=\"https:\/\/lluita.org\/en\/\"><span data-contrast=\"none\">Fundaci\u00f3 Lluita contra les Infeccions<\/span><\/a> <b><span data-contrast=\"auto\">analyses the available evidence on the use of this immunotherapy<\/span><\/b><span data-contrast=\"auto\"> to treat severe infections. The study focuses on <\/span><b><span data-contrast=\"auto\">invasive fungal infections<\/span><\/b><span data-contrast=\"auto\"> in immunocompromised people, in other words, those with weakened immune systems. <\/span><\/p>\n<p><span data-contrast=\"auto\">The article, published in <\/span><i><span data-contrast=\"auto\">Clinical Microbiology and Infection<\/span><\/i><span data-contrast=\"auto\">, is authored by Dr Pedro Puerta, Dr Carme Bracke and Dr Ignacio Grafia. The authors review preclinical and clinical studies that have explored the use of cells modified with CAR receptors to target fungal, viral and some bacterial infections.<\/span><\/p>\n<p><span data-contrast=\"auto\">This type of therapy <\/span><b><span data-contrast=\"auto\">modifies immune cells so that they can identify a specific target and act against it.<\/span><\/b><span data-contrast=\"auto\"> In oncology, it is mainly used with T lymphocytes, known as CAR-T cells. Researchers are now investigating whether the same principle can be used to enable immune cells to recognise microorganisms responsible for severe infections. <\/span><\/p>\n<h3><b><span data-contrast=\"none\">Fungal infections can have a mortality rate of up to 50% in high-risk patients <\/span><\/b><\/h3>\n<p><span data-contrast=\"auto\">Invasive fungal infections pose a particularly serious problem for people with weakened immune systems, such as <\/span><b><span data-contrast=\"auto\">patients with haematological cancers or people who have received a transplant.<\/span><\/b><span data-contrast=\"auto\"> Even with current antifungal treatments, <\/span><b><span data-contrast=\"auto\">mortality in high-risk populations often exceeds 40% or 50%<\/span><\/b><span data-contrast=\"auto\">. According to the authors, this is compounded by the emergence of fungi that are resistant to available drugs, making these infections even more difficult to treat. <\/span><\/p>\n<p><span data-contrast=\"auto\">This is where CAR-T therapies could offer a different strategy. Given that these infections occur in patients with severely weakened immune systems, the idea is to <\/span><b><span data-contrast=\"auto\">directly infuse immune cells that specifically target the pathogens<\/span><\/b><span data-contrast=\"auto\"> in a similar way to how the immune system would respond in a healthy person. <\/span><i><span data-contrast=\"auto\">\u201cIn these patients, the main problem is not only the infection itself, but also the lack of an effective immune response to control it. CAR-T therapies could make it possible to restore this lost immune function in a targeted way. The studies reviewed have tested different types of modified cells, including T lymphocytes, NK cells and macrophages\u201d<\/span><\/i><span data-contrast=\"auto\">, explains Dr Puerta. <\/span><\/p>\n<p><b><span data-contrast=\"auto\">The results are particularly promising against <\/span><\/b><b><i><span data-contrast=\"auto\">Aspergillus<\/span><\/i><\/b><b><span data-contrast=\"auto\"> spp. and <\/span><\/b><b><i><span data-contrast=\"auto\">Candida <\/span><\/i><\/b><b><span data-contrast=\"auto\">spp<\/span><\/b><b><i><span data-contrast=\"auto\">.<\/span><\/i><\/b><span data-contrast=\"auto\"> In experimental models, several CAR-T strategies have been able to recognise fungal structures, increase antifungal activity, reduce infection burden and improve survival in animal models. Some approaches have also shown promising results in models of infection with <\/span><i><span data-contrast=\"auto\">Cryptococcus<\/span><\/i><span data-contrast=\"auto\"> spp. and <\/span><i><span data-contrast=\"auto\">Fusarium <\/span><\/i><span data-contrast=\"auto\">spp<\/span><i><span data-contrast=\"auto\">.<\/span><\/i><\/p>\n<h3><b><span data-contrast=\"none\">A promising strategy that has yet to demonstrate its full potential<\/span><\/b><\/h3>\n<p><span data-contrast=\"auto\">The potential of CAR-T therapies in infectious diseases is not limited to fungal infections. The review includes studies on HIV, cytomegalovirus, Epstein-Barr virus, hepatitis B and C, and SARS-CoV-2. At the same time, their potential use against certain bacterial infections has also begun to be explored. <\/span><\/p>\n<p><span data-contrast=\"auto\">In fact, in the case of HIV, clinical studies using different generations of CAR-T cells already exist. Some strategies have succeeded in reducing the viral reservoir, although they have not yet enabled definitive control of the virus after antiretroviral treatment is discontinued. <\/span><\/p>\n<p><span data-contrast=\"auto\">In this respect, despite the initial results, CAR-T therapies for infections are still a long way from being incorporated into routine clinical practice. According to the researchers, their safety in patients with active infections therefore needs to be studied further, as does which patients could benefit from them. Selecting the appropriate target is also a challenge, as microorganisms may differ between species or modify the structures that CAR-T cells need to recognise. <\/span><\/p>\n<p><span data-contrast=\"auto\">The authors suggest that the <\/span><b><span data-contrast=\"auto\">first applications could focus on patients with severe infections that do not respond to standard treatments or are resistant to multiple drugs,<\/span><\/b><span data-contrast=\"auto\"> particularly when the available therapeutic options are limited. Future clinical studies will need to determine whether this technology can move from being an experimental strategy to becoming a new tool against some of the most difficult infections to treat. <\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>CAR-T therapies, best known for their use in certain blood cancers, could have a new application in the field of infectious diseases. A scientific review involving researchers from the Fundaci\u00f3 Lluita contra les Infeccions analyses the available evidence on the use of this immunotherapy to treat severe infections. The study focuses on invasive fungal infections [&hellip;]<\/p>\n","protected":false},"author":8,"featured_media":28014,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[277],"class_list":["post-28018","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-infections-immunocompromised-patients"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.8 (Yoast SEO v28.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CAR-T therapies open up a new avenue for tackling severe infections in immunocompromised patients - Fundaci\u00f3 Lluita contra les Infeccions<\/title>\n<meta name=\"description\" content=\"CAR-T therapies could open up a new avenue for treating severe infections in immunocompromised patients, particularly those caused by fungi.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/lluita.org\/en\/les-terapies-car-t-obren-una-nova-via-per-combatre-infeccions-greus-en-pacients-immunocompromesos\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CAR-T therapies open up a new avenue for tackling severe infections in immunocompromised patients\" \/>\n<meta property=\"og:description\" content=\"CAR-T therapies could open up a new avenue for treating severe infections in immunocompromised patients, particularly those caused by fungi.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/lluita.org\/en\/les-terapies-car-t-obren-una-nova-via-per-combatre-infeccions-greus-en-pacients-immunocompromesos\/\" \/>\n<meta property=\"og:site_name\" content=\"Fundaci\u00f3 Lluita contra les Infeccions\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-06T16:11:38+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-10T16:50:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/lluita.org\/custom\/uploads\/2026\/11\/Lluita-setembre-2026-33-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1707\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"LLUITA Admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"LLUITA Admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/lluita.org\\\/en\\\/les-terapies-car-t-obren-una-nova-via-per-combatre-infeccions-greus-en-pacients-immunocompromesos\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/lluita.org\\\/en\\\/les-terapies-car-t-obren-una-nova-via-per-combatre-infeccions-greus-en-pacients-immunocompromesos\\\/\"},\"author\":{\"name\":\"LLUITA Admin\",\"@id\":\"https:\\\/\\\/lluita.org\\\/#\\\/schema\\\/person\\\/ebbfd4b21b6e55289e039158312b195a\"},\"headline\":\"CAR-T therapies open up a new avenue for tackling severe infections in immunocompromised patients\",\"datePublished\":\"2026-11-06T16:11:38+00:00\",\"dateModified\":\"2026-11-10T16:50:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/lluita.org\\\/en\\\/les-terapies-car-t-obren-una-nova-via-per-combatre-infeccions-greus-en-pacients-immunocompromesos\\\/\"},\"wordCount\":659,\"image\":{\"@id\":\"https:\\\/\\\/lluita.org\\\/en\\\/les-terapies-car-t-obren-una-nova-via-per-combatre-infeccions-greus-en-pacients-immunocompromesos\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/lluita.org\\\/custom\\\/uploads\\\/2026\\\/11\\\/Lluita-setembre-2026-33-scaled.jpg\",\"articleSection\":[\"Infections in immunocompromised patients\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/lluita.org\\\/en\\\/les-terapies-car-t-obren-una-nova-via-per-combatre-infeccions-greus-en-pacients-immunocompromesos\\\/\",\"url\":\"https:\\\/\\\/lluita.org\\\/en\\\/les-terapies-car-t-obren-una-nova-via-per-combatre-infeccions-greus-en-pacients-immunocompromesos\\\/\",\"name\":\"CAR-T therapies open up a new avenue for tackling severe infections in immunocompromised patients - Fundaci\u00f3 Lluita contra les Infeccions\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/lluita.org\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/lluita.org\\\/en\\\/les-terapies-car-t-obren-una-nova-via-per-combatre-infeccions-greus-en-pacients-immunocompromesos\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/lluita.org\\\/en\\\/les-terapies-car-t-obren-una-nova-via-per-combatre-infeccions-greus-en-pacients-immunocompromesos\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/lluita.org\\\/custom\\\/uploads\\\/2026\\\/11\\\/Lluita-setembre-2026-33-scaled.jpg\",\"datePublished\":\"2026-11-06T16:11:38+00:00\",\"dateModified\":\"2026-11-10T16:50:10+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/lluita.org\\\/#\\\/schema\\\/person\\\/ebbfd4b21b6e55289e039158312b195a\"},\"description\":\"CAR-T therapies could open up a new avenue for treating severe infections in immunocompromised patients, particularly those caused by fungi.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/lluita.org\\\/en\\\/les-terapies-car-t-obren-una-nova-via-per-combatre-infeccions-greus-en-pacients-immunocompromesos\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/lluita.org\\\/en\\\/les-terapies-car-t-obren-una-nova-via-per-combatre-infeccions-greus-en-pacients-immunocompromesos\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/lluita.org\\\/en\\\/les-terapies-car-t-obren-una-nova-via-per-combatre-infeccions-greus-en-pacients-immunocompromesos\\\/#primaryimage\",\"url\":\"https:\\\/\\\/lluita.org\\\/custom\\\/uploads\\\/2026\\\/11\\\/Lluita-setembre-2026-33-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/lluita.org\\\/custom\\\/uploads\\\/2026\\\/11\\\/Lluita-setembre-2026-33-scaled.jpg\",\"width\":2560,\"height\":1707},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/lluita.org\\\/en\\\/les-terapies-car-t-obren-una-nova-via-per-combatre-infeccions-greus-en-pacients-immunocompromesos\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inici\",\"item\":\"https:\\\/\\\/lluita.org\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CAR-T therapies open up a new avenue for tackling severe infections in immunocompromised patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/lluita.org\\\/#website\",\"url\":\"https:\\\/\\\/lluita.org\\\/\",\"name\":\"Fundaci\u00f3 Lluita contra les Infeccions\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/lluita.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/lluita.org\\\/#\\\/schema\\\/person\\\/ebbfd4b21b6e55289e039158312b195a\",\"name\":\"LLUITA Admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f51e89f2d1a045d315b4e165e3eb08f2b3fd6e86e5b4f0aa29788174420124f5?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f51e89f2d1a045d315b4e165e3eb08f2b3fd6e86e5b4f0aa29788174420124f5?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f51e89f2d1a045d315b4e165e3eb08f2b3fd6e86e5b4f0aa29788174420124f5?s=96&d=mm&r=g\",\"caption\":\"LLUITA Admin\"},\"url\":\"https:\\\/\\\/lluita.org\\\/en\\\/author\\\/lluita\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CAR-T therapies open up a new avenue for tackling severe infections in immunocompromised patients - Fundaci\u00f3 Lluita contra les Infeccions","description":"CAR-T therapies could open up a new avenue for treating severe infections in immunocompromised patients, particularly those caused by fungi.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/lluita.org\/en\/les-terapies-car-t-obren-una-nova-via-per-combatre-infeccions-greus-en-pacients-immunocompromesos\/","og_locale":"en_US","og_type":"article","og_title":"CAR-T therapies open up a new avenue for tackling severe infections in immunocompromised patients","og_description":"CAR-T therapies could open up a new avenue for treating severe infections in immunocompromised patients, particularly those caused by fungi.","og_url":"https:\/\/lluita.org\/en\/les-terapies-car-t-obren-una-nova-via-per-combatre-infeccions-greus-en-pacients-immunocompromesos\/","og_site_name":"Fundaci\u00f3 Lluita contra les Infeccions","article_published_time":"2026-11-06T16:11:38+00:00","article_modified_time":"2026-11-10T16:50:10+00:00","og_image":[{"width":2560,"height":1707,"url":"https:\/\/lluita.org\/custom\/uploads\/2026\/11\/Lluita-setembre-2026-33-scaled.jpg","type":"image\/jpeg"}],"author":"LLUITA Admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"LLUITA Admin","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/lluita.org\/en\/les-terapies-car-t-obren-una-nova-via-per-combatre-infeccions-greus-en-pacients-immunocompromesos\/#article","isPartOf":{"@id":"https:\/\/lluita.org\/en\/les-terapies-car-t-obren-una-nova-via-per-combatre-infeccions-greus-en-pacients-immunocompromesos\/"},"author":{"name":"LLUITA Admin","@id":"https:\/\/lluita.org\/#\/schema\/person\/ebbfd4b21b6e55289e039158312b195a"},"headline":"CAR-T therapies open up a new avenue for tackling severe infections in immunocompromised patients","datePublished":"2026-11-06T16:11:38+00:00","dateModified":"2026-11-10T16:50:10+00:00","mainEntityOfPage":{"@id":"https:\/\/lluita.org\/en\/les-terapies-car-t-obren-una-nova-via-per-combatre-infeccions-greus-en-pacients-immunocompromesos\/"},"wordCount":659,"image":{"@id":"https:\/\/lluita.org\/en\/les-terapies-car-t-obren-una-nova-via-per-combatre-infeccions-greus-en-pacients-immunocompromesos\/#primaryimage"},"thumbnailUrl":"https:\/\/lluita.org\/custom\/uploads\/2026\/11\/Lluita-setembre-2026-33-scaled.jpg","articleSection":["Infections in immunocompromised patients"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/lluita.org\/en\/les-terapies-car-t-obren-una-nova-via-per-combatre-infeccions-greus-en-pacients-immunocompromesos\/","url":"https:\/\/lluita.org\/en\/les-terapies-car-t-obren-una-nova-via-per-combatre-infeccions-greus-en-pacients-immunocompromesos\/","name":"CAR-T therapies open up a new avenue for tackling severe infections in immunocompromised patients - Fundaci\u00f3 Lluita contra les Infeccions","isPartOf":{"@id":"https:\/\/lluita.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/lluita.org\/en\/les-terapies-car-t-obren-una-nova-via-per-combatre-infeccions-greus-en-pacients-immunocompromesos\/#primaryimage"},"image":{"@id":"https:\/\/lluita.org\/en\/les-terapies-car-t-obren-una-nova-via-per-combatre-infeccions-greus-en-pacients-immunocompromesos\/#primaryimage"},"thumbnailUrl":"https:\/\/lluita.org\/custom\/uploads\/2026\/11\/Lluita-setembre-2026-33-scaled.jpg","datePublished":"2026-11-06T16:11:38+00:00","dateModified":"2026-11-10T16:50:10+00:00","author":{"@id":"https:\/\/lluita.org\/#\/schema\/person\/ebbfd4b21b6e55289e039158312b195a"},"description":"CAR-T therapies could open up a new avenue for treating severe infections in immunocompromised patients, particularly those caused by fungi.","breadcrumb":{"@id":"https:\/\/lluita.org\/en\/les-terapies-car-t-obren-una-nova-via-per-combatre-infeccions-greus-en-pacients-immunocompromesos\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/lluita.org\/en\/les-terapies-car-t-obren-una-nova-via-per-combatre-infeccions-greus-en-pacients-immunocompromesos\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/lluita.org\/en\/les-terapies-car-t-obren-una-nova-via-per-combatre-infeccions-greus-en-pacients-immunocompromesos\/#primaryimage","url":"https:\/\/lluita.org\/custom\/uploads\/2026\/11\/Lluita-setembre-2026-33-scaled.jpg","contentUrl":"https:\/\/lluita.org\/custom\/uploads\/2026\/11\/Lluita-setembre-2026-33-scaled.jpg","width":2560,"height":1707},{"@type":"BreadcrumbList","@id":"https:\/\/lluita.org\/en\/les-terapies-car-t-obren-una-nova-via-per-combatre-infeccions-greus-en-pacients-immunocompromesos\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inici","item":"https:\/\/lluita.org\/en\/"},{"@type":"ListItem","position":2,"name":"CAR-T therapies open up a new avenue for tackling severe infections in immunocompromised patients"}]},{"@type":"WebSite","@id":"https:\/\/lluita.org\/#website","url":"https:\/\/lluita.org\/","name":"Fundaci\u00f3 Lluita contra les Infeccions","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/lluita.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/lluita.org\/#\/schema\/person\/ebbfd4b21b6e55289e039158312b195a","name":"LLUITA Admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/f51e89f2d1a045d315b4e165e3eb08f2b3fd6e86e5b4f0aa29788174420124f5?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/f51e89f2d1a045d315b4e165e3eb08f2b3fd6e86e5b4f0aa29788174420124f5?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f51e89f2d1a045d315b4e165e3eb08f2b3fd6e86e5b4f0aa29788174420124f5?s=96&d=mm&r=g","caption":"LLUITA Admin"},"url":"https:\/\/lluita.org\/en\/author\/lluita\/"}]}},"_links":{"self":[{"href":"https:\/\/lluita.org\/en\/wp-json\/wp\/v2\/posts\/28018","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lluita.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lluita.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lluita.org\/en\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/lluita.org\/en\/wp-json\/wp\/v2\/comments?post=28018"}],"version-history":[{"count":4,"href":"https:\/\/lluita.org\/en\/wp-json\/wp\/v2\/posts\/28018\/revisions"}],"predecessor-version":[{"id":28034,"href":"https:\/\/lluita.org\/en\/wp-json\/wp\/v2\/posts\/28018\/revisions\/28034"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/lluita.org\/en\/wp-json\/wp\/v2\/media\/28014"}],"wp:attachment":[{"href":"https:\/\/lluita.org\/en\/wp-json\/wp\/v2\/media?parent=28018"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lluita.org\/en\/wp-json\/wp\/v2\/categories?post=28018"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}